PA.Sig: Pyroptosis-Apoptosis Gene Signature for Glioma Prognosis and Immune Landscape

Huaichao Zhang developed a pyroptosis–apoptosis–associated gene signature (PA.Sig) using transcriptomic and clinical data from TCGA-GBMLGG and external validation cohorts. The signature stratifies glioma patients into high- and low-risk groups with significantly different overall survival. The dataset was last updated on 2026-05-21 and is shared under a CC-BY-4.0 license.

Use Cases

• Prognostic risk stratification based on a cell death-associated gene signature.
• Analysis of tumor immune microenvironment features linked to inflammatory cell death.
• Correlation of malignant cell states (e.g., MES-like, AC/MES-like) with genomic alterations.
• Investigation of therapeutic response to chemotherapy agents in relation to cell death programs.

Strengths

• Derived from established public cohorts including TCGA-GBMLGG and external validation sets.
• Signature was functionally validated in glioma cell lines treated with chemotherapeutic agents.
• Analyses include single-cell RNA sequencing to delineate malignant cell states and intercellular communication.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary file is a 181.4 KB PDF, which is a small document; the underlying data files are not specified.

Provenance

Source

Transcriptomic and clinical data from TCGA-GBMLGG and external validation cohorts.

Collection Method

Integrative survival modeling, genomic alteration profiling, pathway enrichment, and single-cell RNA sequencing analysis.

Freshness

Last updated 2026-05-21 04:39:04; freshness should be verified.